Sigma Planning Corp Trims Holdings in IN8bio, Inc. (NASDAQ:INAB)

Sigma Planning Corp reduced its holdings in shares of IN8bio, Inc. (NASDAQ:INAB) by 53.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 132,230 shares of the company’s stock after selling 152,820 shares during the period. Sigma Planning Corp’s holdings in IN8bio were worth $182,000 as of its most recent filing with the SEC.

Separately, Rock Creek Group LP boosted its stake in shares of IN8bio by 98.3% during the third quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock worth $157,000 after buying an additional 75,000 shares during the period. Hedge funds and other institutional investors own 92.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on INAB shares. Laidlaw initiated coverage on IN8bio in a research note on Monday, March 18th. They set a “buy” rating and a $7.50 price objective for the company. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of IN8bio in a research note on Wednesday, April 10th.

IN8bio Stock Down 4.8 %

Shares of NASDAQ:INAB opened at $0.99 on Tuesday. IN8bio, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $3.48. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $1.12 and its 200-day simple moving average is $1.16. The company has a market cap of $31.67 million, a price-to-earnings ratio of -0.98 and a beta of -0.01.

IN8bio (NASDAQ:INAB) last released its earnings results on Thursday, March 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.05). As a group, equities research analysts predict that IN8bio, Inc. will post -0.64 earnings per share for the current year.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.